Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (271-280 of 420) with videos related to

Pageof 42
Sort By:
Diagnostic Microbiology and Infectious Disease|July 9, 2020
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteriaHelio S Sader, Mariana Castanheira, Jennifer M Streit, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2012
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec typesMariana Castanheira, Helio S Sader, David J Farrell, et al.
International Journal of Antimicrobial Agents|February 14, 2024
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022)Helio S Sader, Cecilia G Carvalhaes, John H Kimbrough, et al.
Microbiology Spectrum|October 10, 2024
<i>In vitro</i> activity assessment of cefiderocol against Enterobacterales, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter</i> spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsJohn H Kimbrough, Joshua M Maher, Helio S Sader, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-Avibactam and Comparator Agents (2019-2023)Helio S Sader, Timothy B Doyle, John H Kimbrough, et al.
Antibiotics (Basel, Switzerland)|June 27, 2024
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and <i>Pseudomonas aeruginosa</i> from Intensive Care Unit and Non-Intensive Care Unit PatientsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
Diagnostic Microbiology and Infectious Disease|July 20, 2010
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance resultsShannon D Putnam, Helio S Sader, Gary J Moet, et al.
The Journal of Antimicrobial Chemotherapy|November 27, 2004
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)Shawn A Messer, Jeffrey T Kirby, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United StatesRodrigo E Mendes, Helio S Sader, Robert K Flamm, et al.
Pageof 42

Showing results (271-280 of 420) with videos related to

Sort By:
Pageof 42
Diagnostic Microbiology and Infectious Disease|July 9, 2020
Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteriaHelio S Sader, Mariana Castanheira, Jennifer M Streit, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2012
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec typesMariana Castanheira, Helio S Sader, David J Farrell, et al.
International Journal of Antimicrobial Agents|February 14, 2024
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022)Helio S Sader, Cecilia G Carvalhaes, John H Kimbrough, et al.
Microbiology Spectrum|October 10, 2024
<i>In vitro</i> activity assessment of cefiderocol against Enterobacterales, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter</i> spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitalsJohn H Kimbrough, Joshua M Maher, Helio S Sader, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-Avibactam and Comparator Agents (2019-2023)Helio S Sader, Timothy B Doyle, John H Kimbrough, et al.
Antibiotics (Basel, Switzerland)|June 27, 2024
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and <i>Pseudomonas aeruginosa</i> from Intensive Care Unit and Non-Intensive Care Unit PatientsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
Diagnostic Microbiology and Infectious Disease|July 20, 2010
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance resultsShannon D Putnam, Helio S Sader, Gary J Moet, et al.
The Journal of Antimicrobial Chemotherapy|November 27, 2004
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)Shawn A Messer, Jeffrey T Kirby, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesDavid J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United StatesRodrigo E Mendes, Helio S Sader, Robert K Flamm, et al.
Pageof 42